Should I Buy Dexcom, Inc. (DXCM)? Finance YouTuber Analysis

The YouTuber advises waiting for a dip before buying Dexcom, despite a 49% upside to analyst targets. Concerns about GLP-1 weight loss drugs impacting demand for diabetes monitoring solutions persist, and upcoming approvals of weight loss pills are expected to negatively affect sentiment again, making the current timing unfavorable.

“So this is one where I would wait for another dip to start buying in.”

The analyst recommends Dexcom due to its strong growth in diabetes monitoring, expecting 24% revenue growth this year. He believes the company is uniquely positioned with both hardware and software solutions, giving it a competitive advantage. While acknowledging the high valuation, he argues that the stock appears to be a good value compared to its historical average, provided revenue growth continues.

“Dexcom here is uniquely positioned in monitoring with both hardware and software for diabetics with with apps for connectivity with their family and Healthcare Providers I think that gives us a competitive advantage against some of the other device makers and monitors in the space.”

Despite a good balance sheet and strong sales growth forecasts, the YouTuber finds Dexcom shares 'terrifically expensive' at about 12 times price-to-sales. He would prefer to see the shares come down before considering a purchase.

“Shares are still terrifically expensive at about 12 times on a price to sales ratio I'd want to see these shares come down before I buy”

The analyst views Dexcom as a potential bargain after a significant stock drop due to a lowered outlook, which he attributes to internal sales issues rather than market demand. He notes the company's strong historical growth in operating cash flow and rising margins, suggesting a turnaround story with substantial upside potential, even with conservative valuation multiples.

“insofern halte ich die Aktie jetzt erstmal nicht für ganz uninteressant”